By Bill Berkrot (Reuters) - An attempt by Merck & Co to shorten hepatitis C treatment to just four weeks by adding Gilead Sciences Inc's huge selling Sovaldi to its own oral two-drug combination came nowhere near the desired efficacy due to a high rate of relapses, according to interim data from a midstage study. Several companies have been working to find ways to further reduce the number of weeks of treatment needed, while keeping cure rates above 90 percent. ...
via Health News Headlines - Yahoo News
Read More Here.. 
Lake forest health and fitness http://ift.tt/1Eiu0ID
No comments:
Post a Comment